Regeneron Pharmaceuticals, Inc. Stock: +11.82% Amid Quarterly Results Exceeding Expectations
The stock of American pharmaceutical giant Regeneron Pharmaceuticals closed sharply higher on Tuesday, driven by the release of third-quarter 2025 results that significantly exceeded Wall Street forecasts. This surge stands in stark contrast to the stock's struggles over the past year, marked by a nearly 30% loss. The announcement of successful management of its therapeutic portfolio and robust demand for its key treatments has revived investor interest.
Daily and Weekly Market Dynamics
Regeneron Pharmaceuticals finished at $654.48, marking an 11.82% increase from the previous session's close. A volume of 2.1 million shares was traded during the day, representing 2% of the traded capitalization, indicating significant market mobilization around this stock. This daily increase is part of a broader movement of a particularly positive week, with a weekly performance of 12.97%. The broader market also advanced, with the Nasdaq up 0.78% at 24,978.56 points. However, this recent momentum contrasts sharply with the annual trajectory of the stock, which has seen a decline of 29.52% over the past twelve months. This prolonged downturn had created a significant gap with its benchmark index, the Nasdaq, which had advanced 26.15% over the same period. The release of quarterly results late Tuesday morning thus provided buyers a concrete reason to revisit the stock, after a long phase of underperformance.
Robust Financial Performance in Q3
The group revealed solidly upward-oriented business figures. Third-quarter revenue was $3.75 billion, surpassing the consensus forecast of $3.59 billion. Adjusted earnings per share reached $11.83 versus an expectation of $9.59, marking a substantial exceedance. Dupixent, the flagship treatment for eczema, continues to show remarkable strength, benefiting from sustained demand that had already impressed during the results announcement of its co-developer Sanofi the previous week. Libtayo, the group's skin cancer treatment, generated sales of $365 million, outperforming the expected consensus of $343.75 million. Eylea, Regeneron's ophthalmic drug for eye diseases, has a more mixed trajectory. Despite increased competitive pressure, particularly from Roche's Vabysmo, the 8-milligram high-dose version developed with Bayer showed a 10% annual growth in the U.S., generating $431 million in sales for the quarter. This dynamic suggests that the group is managing to convert some of its clientele to the new formulation offering spaced injections.
Stock Price Dynamics and Future Outlook
In terms of stock price dynamics, the stock is making a notable catch-up after a prolonged period of weakness. Tuesday's positive reaction indicates that previous concerns about the group's profitability and the competitiveness of its portfolio have partially dissipated in light of the concrete figures from the last quarter. The question of the stock's ability to continue its recovery will depend on the consolidation of this demand for Dupixent and Libtayo, as well as on the expected progress for Eylea towards 2026, when new label extensions are anticipated.
